Graft rejection therapy enters Phase III

Article

GS-101, Gene Signal's experimental topical ophthalmic solution designed to prevent the rejection of corneal grafts, has entered Phase III trials.

GS-101, Gene Signal's experimental topical ophthalmic solution designed to prevent the rejection of corneal grafts, has entered Phase III trials. The solution, an antisense oligonucleotide, inhibits the expression of insulin-receptor substrate-1 (IRS-1), which is essential for corneal neovascularization.

The results of the multicentre, double-blind, randomized Phase II trial, presented at this year's meeting of the American Academy of Ophthalmology (AAO) by Professor Claus Cursiefen of the department of ophthalmology at Germany's Friedrich Alexander University, demonstrated the safety and efficacy of the solution in suppressing the formation of new blood vessels in the cornea. Over the three month study period, in which 40 patients were treated, corneal neovascularization progressed in 100% of subjects receiving placebo therapy; patients treated with GS-101 twice daily (at doses of 43 µg, 86 µg and 172 µg) achieved up to 86% regression.

In addition to the Phase III trial of GS-101, Gene Signal is developing several other antisense oligonucleotides for the treatment of diseases related to angiogenesis.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
Related Content
© 2025 MJH Life Sciences

All rights reserved.